

### **Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF**

**Boulogne-Billancourt (France), July 30, 2019** – Under the liquidity agreement entrusted by IPSEN to NATIXIS ODDO BHF relating to the ordinary shares admitted to trading on Euronext Paris, as amended in accordance with AMF Decision 2018-01 of July 2 2018 on the introduction of liquidity agreements on equity securities as an accepted market practice, the following resources were included to the dedicated liquidity account, as of June 30, 2019:

- 4,483 shares
- €4,207,301.00

It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:

- 91,006 shares
- €152,357.11

Between January 1, 2019 and June 30, 2019 have been executed:

- 1,298 purchase transactions
- 1,528 sell transactions

Under the same period, the volumes traded represented:

- 192,541 shares and €22,372,177.75 to the purchase
- 209,706 shares and €24,369,037.70 to the sell

#### **About Ipsen**

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit [www.ipсен.com](http://www.ipсен.com).

**For further information:**

**Media**

**Christian Marcoux**

Senior Vice President, Global Communications  
+33 (0)1 58 33 67 94  
[christian.marcoux@ipsen.com](mailto:christian.marcoux@ipsen.com)

**Fanny Allaire**

Director, Ipsen France Hub, Global Communications  
+33 (0) 1 58 33 58 96  
[fanny.allaire@ipsen.com](mailto:fanny.allaire@ipsen.com)

**Financial Community**

**Eugenia Litz**

Vice President, Investor Relations  
+44 (0) 1753 627721  
[eugenia.litz@ipsen.com](mailto:eugenia.litz@ipsen.com)

**Myriam Koutchinsky**

Investor Relations Manager  
+33 (0)1 58 33 51 04  
[myriam.koutchinsky@ipsen.com](mailto:myriam.koutchinsky@ipsen.com)